Literature DB >> 33409874

Sulforaphane Bioavailability and Effects on Blood Pressure in Women with Pregnancy Hypertension.

A G Langston-Cox1, D Anderson2, D J Creek2, K R Palmer1, S A Marshall1, E M Wallace3.   

Abstract

Sulforaphane, an isothiocyanate found in cruciferous vegetables such as broccoli, shows promise as an adjuvant therapy for preeclampsia. To inform future clinical trials, we set out to determine the bioavailability of sulforaphane in non-pregnant and preeclamptic women. In six healthy female volunteers, we performed a crossover trial to compare the bioavailability of sulforaphane and metabolites afforded by an activated and non-activated broccoli extract preparation. We then undertook a dose escalation study of the activated broccoli extract in 12 women with pregnancy hypertension. In non-pregnant women, an equivalent dose of activated broccoli extract gave higher levels of sulforaphane and metabolites than a non-activated extract (p < 0.0001) and greater area under the curve (AUC) (3559 nM vs. 2172 nM, p = 0.03). Compared to non-pregnant women, in women with preeclampsia, the same dose of activated extract gave lower levels of total metabolites (p < 0.000) and AUC (3559 nM vs. 1653 nM, p = 0.007). Doubling the dose of the activated extract in women with preeclampsia doubled levels of sulforaphane and metabolites (p = 0.02) and AUC (1653 nM vs. 3333 nM, p = 0.02). In women with preeclampsia, activated broccoli extract was associated with modest decreases in diastolic blood pressure (p = 0.05) and circulating levels of sFlt-1 (p = 0.0002). A myrosinase-activated sulforaphane formulation affords better sulforaphane bioavailability than a non-activated formulation. Higher doses of sulforaphane are required to achieve likely effective doses in pregnant women than in non-pregnant women. Sulforaphane may improve endothelial function and blood pressure in women with pregnancy hypertension.

Entities:  

Keywords:  Antioxidant; Bioavailability; Broccoli; Preeclampsia; Sulforaphane

Mesh:

Substances:

Year:  2021        PMID: 33409874     DOI: 10.1007/s43032-020-00439-5

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  30 in total

1.  Evidence for multiple circulating factors in preeclampsia.

Authors:  Jenny E Myers; Sarah Hart; Stuart Armstrong; Gary J Mires; Robert Beynon; Simon J Gaskell; Philip N Baker
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

Review 2.  First-trimester maternal factors and biomarker screening for preeclampsia.

Authors:  Leona C Poon; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2014-05-21       Impact factor: 3.050

3.  Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

Authors:  Fiona C Brownfoot; Roxanne Hastie; Natalie J Hannan; Ping Cannon; Laura Tuohey; Laura J Parry; Sevvandi Senadheera; Sebastian E Illanes; Tu'uhevaha J Kaitu'u-Lino; Stephen Tong
Journal:  Am J Obstet Gynecol       Date:  2015-12-22       Impact factor: 8.661

4.  Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies.

Authors:  Rebecca Lim; Rutu Acharya; Pavitra Delpachitra; Sebastian Hobson; Christopher G Sobey; Grant R Drummond; Euan M Wallace
Journal:  Am J Obstet Gynecol       Date:  2014-07-18       Impact factor: 8.661

5.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.

Authors:  Daniel L Rolnik; David Wright; Liona C Poon; Neil O'Gorman; Argyro Syngelaki; Catalina de Paco Matallana; Ranjit Akolekar; Simona Cicero; Deepa Janga; Mandeep Singh; Francisca S Molina; Nicola Persico; Jacques C Jani; Walter Plasencia; George Papaioannou; Kinneret Tenenbaum-Gavish; Hamutal Meiri; Sveinbjorn Gizurarson; Kate Maclagan; Kypros H Nicolaides
Journal:  N Engl J Med       Date:  2017-06-28       Impact factor: 91.245

6.  The two stage model of preeclampsia: variations on the theme.

Authors:  J M Roberts; C A Hubel
Journal:  Placenta       Date:  2008-12-13       Impact factor: 3.481

7.  Advanced oxidation protein products enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts: a possible link between oxidative stress and preeclampsia.

Authors:  Q T Huang; S S Wang; M Zhang; L P Huang; J W Tian; Y H Yu; Z J Wang; M Zhong
Journal:  Placenta       Date:  2013-07-27       Impact factor: 3.481

Review 8.  Pre-eclampsia.

Authors:  Ben W J Mol; Claire T Roberts; Shakila Thangaratinam; Laura A Magee; Christianne J M de Groot; G Justus Hofmeyr
Journal:  Lancet       Date:  2015-09-02       Impact factor: 79.321

Review 9.  Angiogenic factors and preeclampsia.

Authors:  Sharon E Maynard; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

10.  Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.

Authors:  Kenji Onda; Stephen Tong; Sally Beard; Natalie Binder; Masanaga Muto; Sevvandi N Senadheera; Laura Parry; Mark Dilworth; Lewis Renshall; Fiona Brownfoot; Roxanne Hastie; Laura Tuohey; Kirsten Palmer; Toshihiko Hirano; Masahito Ikawa; Tu'uhevaha Kaitu'u-Lino; Natalie J Hannan
Journal:  Hypertension       Date:  2017-01-23       Impact factor: 10.190

View more
  3 in total

1.  An experimental evaluation of the efficacy of perinatal sulforaphane supplementation to decrease the incidence and severity of vinclozolin-induced hypospadias in the mouse model.

Authors:  Ciro M Amato; Ariel Fricke; Sahiti Marella; Joshua P Mogus; Michael Bereman; Krista A McCoy
Journal:  Toxicol Appl Pharmacol       Date:  2022-07-26       Impact factor: 4.460

Review 2.  Potential Effects of Natural H2S-Donors in Hypertension Management.

Authors:  Eugenia Piragine; Valentina Citi; Kim Lawson; Vincenzo Calderone; Alma Martelli
Journal:  Biomolecules       Date:  2022-04-14

Review 3.  Melatonin for the Management of Preeclampsia: A Review.

Authors:  Annie Langston-Cox; Sarah A Marshall; Daisy Lu; Kirsten R Palmer; Euan M Wallace
Journal:  Antioxidants (Basel)       Date:  2021-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.